MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
ROCKVILLE, Md., Sept. 07, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
A live webcast of REGENXBIO’s presentation is scheduled to begin at 12:55 p.m. ET and will feature a fireside chat with Kenneth T. Mills, President and Chief Executive Officer. The live webcast can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.
REGENXBIO representatives will also attend the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 16, 2016 in London to meet one-on-one with investors, analysts and other potential corporate partners.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO's licensees.
CONTACT: Investors Elizabeth Broder, 646-378-2945 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
